Corvex (MOVE) Q4 2024 earnings summary

Executive summary

• Launched Evie Ring, a women-focused wearable, in Nov 2023 as a general wellness device; FDA 510(k) clearance for EvieMED Ring’s pulse oximetry feature received in Nov 2024, enabling prescription-based sales for clinical and remote monitoring applications.

• Developing proprietary SoC for non-invasive blood pressure and glucose monitoring; clinical studies show promising accuracy for blood pressure, with ongoing algorithm refinement.

• Company operates as a single segment, focusing on research, development, and commercialization of health monitoring devices.

Financial highlights

• Revenue for 2024 was $1.0 million, up from $0 in 2023, driven by Evie Ring sales.

• Net loss for 2024 was $23.7 million, an improvement from $29.3 million in 2023.

• Research and development expenses decreased to $11.2 million in 2024 from $16.9 million in 2023.

• Sales, general, and administrative expenses were $11.0 million in 2024, down from $12.8 million in 2023.

• Cash and cash equivalents at year-end 2024 were $7.9 million; company used $22.5 million in operating activities during 2024.

• Accumulated deficit reached $148.1 million as of December 31, 2024.

Outlook and guidance

• Cash is not expected to fund operations beyond Q2 2025; additional capital is required to continue operations and product development.

• Company anticipates continued annual losses as it invests in commercialization and R&D.

• Exploring financing options, including equity offerings and strategic partnerships.